See more : Prozone Realty Limited (PROZONER.BO) Income Statement Analysis – Financial Results
Complete financial analysis of Precision BioSciences, Inc. (DTIL) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Precision BioSciences, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Jialijia Group Corporation Limited (RZZN) Income Statement Analysis – Financial Results
- TGI Solar Power Group Inc. (TSPG) Income Statement Analysis – Financial Results
- Bureau Veritas SA (BVVBY) Income Statement Analysis – Financial Results
- Mivtach Shamir Holdings Ltd (MISH.TA) Income Statement Analysis – Financial Results
- Victoria PLC (VCCTF) Income Statement Analysis – Financial Results
Precision BioSciences, Inc. (DTIL)
About Precision BioSciences, Inc.
Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing and ex vivo allogeneic CAR T therapies in the United States. It offers ARCUS, a genome editing platform to cure genetic disorders. The company also provides Ex vivo Allogeneic CAR T Immunotherapy, a form of immunotherapy in which T cell, a specific type of immune cell is genetically engineered to recognize and kill cancer cells; PBCAR0191, which is in Phase 1/2a clinical trial in adult patients with R/R NHL or R/R B-cell precursor acute lymphoblastic leukemia, or B-ALL; PBCAR19B, an anti-CD19 CAR T candidate built on the stealth cell platform utilizing a single-step gene edit to minimize the risk of chromosome abnormalities; and PBCAR269A, an investigational allogeneic CAR T immunotherapy targeting BCMA for the treatment of R/R multiple myeloma. The company has development and commercial license agreement with Les Laboratoires Servier to develop allogeneic chimeric antigen receptor T cell therapies for antigen targets, hematological cancer targets beyond CD19, and solid tumor targets; Tiziana Life Sciences to evaluate foralumab, a fully human anti-CD3 monoclonal antibody as a lymphodepleting agent for the potential treatment of cancers; and iECURE, Inc. to develop ARCUS-based gene editing therapies. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 48.73M | 25.10M | 115.53M | 24.29M | 22.24M | 10.88M | 6.48M | 7.02M |
| Cost of Revenue | 8.26M | 9.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 40.47M | 16.09M | 115.53M | 24.29M | 22.24M | 10.88M | 6.48M | 7.02M |
| Gross Profit Ratio | 83.06% | 64.12% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Research & Development | 53.38M | 83.94M | 115.24M | 98.06M | 82.42M | 45.12M | 20.32M | 9.10M |
| General & Administrative | 39.09M | 41.53M | 39.69M | 36.05M | 27.03M | 13.67M | 8.02M | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 39.09M | 41.53M | 39.69M | 36.05M | 27.03M | 13.67M | 8.02M | 6.10M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | -9.76M | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 92.46M | 125.46M | 154.93M | 134.11M | 109.44M | 58.80M | 28.34M | 15.20M |
| Cost & Expenses | 92.46M | 125.46M | 154.93M | 134.11M | 109.44M | 58.80M | 28.34M | 15.84M |
| Interest Income | 7.69M | 3.47M | 208.00K | 822.00K | 4.27M | 1.88M | 872.00K | 570.00K |
| Interest Expense | 2.23M | 1.11M | 132.00K | 0.00 | 182.00K | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 8.26M | 9.00M | 10.20M | 9.81M | 5.32M | 2.35M | 1.44M | 640.00K |
| EBITDA | -32.04M | -62.79M | -20.27M | -99.19M | -87.38M | -43.68M | -20.42M | -8.19M |
| EBITDA Ratio | -65.76% | -392.35% | -24.94% | -408.45% | -392.92% | -418.62% | -313.12% | -116.72% |
| Operating Income | -43.74M | -100.37M | -39.40M | -109.83M | -87.20M | -47.91M | -21.97M | -8.83M |
| Operating Income Ratio | -89.76% | -399.90% | -34.11% | -452.25% | -392.14% | -440.25% | -338.90% | -125.84% |
| Total Other Income/Expenses | 1.21M | 27.46M | 8.80M | 822.00K | -5.67M | 1.88M | 872.00K | 572.00K |
| Income Before Tax | -42.53M | -111.64M | -30.60M | -109.01M | -92.88M | -46.04M | -21.10M | -8.26M |
| Income Before Tax Ratio | -87.28% | -444.80% | -26.49% | -448.86% | -417.65% | -423.02% | -325.45% | -117.69% |
| Income Tax Expense | 0.00 | 11.27M | 316.00K | 10.43M | -9.58M | 1.88M | -754.00K | -5.00K |
| Net Income | -61.32M | -122.91M | -30.92M | -109.01M | -83.30M | -46.04M | -21.10M | -8.25M |
| Net Income Ratio | -125.84% | -489.71% | -26.76% | -448.86% | -374.59% | -423.02% | -325.45% | -117.62% |
| EPS | -15.96 | -41.95 | -15.80 | -62.85 | -59.50 | -28.17 | -18.81 | 0.00 |
| EPS Diluted | -15.96 | -41.95 | -15.80 | -62.85 | -59.50 | -28.17 | -18.81 | 0.00 |
| Weighted Avg Shares Out | 3.84M | 2.93M | 1.96M | 1.73M | 1.40M | 1.63M | 1.12M | 1.67B |
| Weighted Avg Shares Out (Dil) | 3.84M | 2.93M | 1.96M | 1.73M | 1.40M | 1.63M | 1.12M | 1.67B |
Precision BioSciences to Report Third Quarter Results on November 7, 2023
Precision BioSciences Presents Preclinical Data Highlighting Capabilities of ARCUS for Gene Insertion and Excision at the European Society of Gene & Cell Therapy (ESGCT) 30th Annual Congress
Precision BioSciences to Present at Upcoming H.C. Wainwright 4th Annual Hepatitis B Virus Conference
Precision BioSciences to Present at the European Society of Gene & Cell Therapy (ESGCT) 30th Annual Congress
Precision BioSciences Receives U.S. Patent Allowance Covering PBGENE-PMM for m.3243-Associated Mitochondrial Diseases
Precision BioSciences Hosts Virtual R&D Day Highlighting its Proprietary ARCUS Technology and Recent In Vivo Gene Editing Program Developments
Precision BioSciences to Attend and Present at Upcoming September Investor Conferences
Precision BioSciences to Host In Vivo Gene Editing R&D Day on September 12, 2023
After Plunging -27.45% in 4 Weeks, Here's Why the Trend Might Reverse for Precision BioSciences (DTIL)
Precision BioSciences Completes Strategic Transaction with Imugene for Azer-Cel in Cancer
Source: https://incomestatements.info
Category: Stock Reports